+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Antiviral Drugs Market Size, Share & Trends Analysis Report By Drug Class, By Application (HIV, Hepatitis, Herpes, Influenza), By Type (Branded, Generics), By Region, and Segment Forecasts, 2021-2028

  • ID: 4118838
  • Report
  • October 2021
  • Region: Global
  • 120 Pages
  • Grand View Research

FEATURED COMPANIES

  • AbbVie Inc.
  • Aurobindo Pharma
  • Cipla Inc.
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc.
The global antiviral drugs market size is expected to reach USD 60.0 billion by 2028. The market is expected to expand at a CAGR of (-0.6%) from 2021 to 2028. This is owing to the loss of patent protection of drugs and the high R&D investment required for developing antiviral drugs. However, the rising prevalence of viral infections and the presence of a potential pipeline for the treatment of HIV infection are expected to fuel the growth over the forecast period.

The increasing prevalence of influenza with other complications such as viral pneumonia, obesity, and the rising geriatric population drives the market growth. Moreover, pneumonia is one of the major causes of death in children worldwide. According to the WHO, Pneumonia causes 808,694 children’s deaths in 2017, accounting for 15.0% of all deaths of children under 5 years old. It is most prevalent in South Asia and the sub-Saharan African region.

The awareness of viral infections, their prevention, and treatment are high in most of the regions. For instance, according to CDC, in 2019, the vaccination rate against influenza was 49% in the U.S., which prevented around 4.4 million influenza infections and around 3,500 deaths in the country. Moreover, the increase in vaccination rate against hepatitis and herpes is affecting the market growth over the forecast period.

Increasing collaboration between government bodies and key players is anticipated to fuel the growth of R&D activities in the development of novel antiviral drugs. For instance, in June 2021, Merck & Co., Inc. entered into a procurement agreement with the U.S. government for molnupiravir, an investigational antiviral for COVID-19 treatment. According to the agreement, the company will receive USD 1.2 billion to supply around 1.7 million courses of the drug to the U.S. government, if molnupiravir receives emergency use authorization or approval by the U.S. FDA.

Companies are adopting strategies such as product development and collaboration to increase their share in the market. For instance, in April 2021, Janssen Pharmaceuticals, Inc. and Cidara Therapeutics, Inc. collaborated to develop Cidara’s Cloudbreak antiviral conjugates for the prevention and treatment of influenza. Moreover, in October 2020, F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc. also collaborated to develop, manufacture, and market AT-527 for the treatment of COVID-19. AT-527 acts as an RNA polymerase inhibitor and stops viral replication.

Favorable initiatives undertaken by government bodies to prevent and treat viral infections are expected to support the management of viral infections. For instance, the U.K. government has launched an antiviral task force to investigate treatments for SARS-CoV-2 infection in home-based settings. It will help prevent the infection and limit the effect of new variants of the SARS-CoV-2 virus. Moreover, the U.S. government is investing more than USD 3 billion to fasten the development of antiviral drugs against COVID-19 and other viral infections.

The upsurge in COVID-19 cases and strong pipeline products is expected to positively impact market growth. According to the WHO, as of 1st September 2021, a total of 217.56 million confirmed cases of COVID-19, including 4.52 million deaths reported. For instance, in May 2021, based on Favipiravir formula antiviral drug BALflue was launched by BAL Pharma, it is used for the treatment of patients with mild to moderate Covid-19 infection as well as used in the treatment of 53 types of influenza viruses. Overall, the outbreak of the COVID-19 pandemic is estimated to propel the market growth, however, it has adversely affected the consumption of antiviral medicines from other applications owing to disruption in the supply chain and limited access to healthcare services during the complete lockdown.

Antiviral Drugs Market Report Highlights

  • An increase in the COVID-19 case is expected to drive market growth in the next 2 to 4 years.
  • The reverse transcriptase inhibitors segment dominated the market due to the high efficacy of drugs and growing prevalence of diseases like HIV and hepatitis B, globally.
  • The HIV segment dominated the market in 2020 and is projected to maintain its dominance over the forecast period, owing to the commercialization of pipeline products over the forecast period.
  • North America dominated the market in 2020 and Asia Pacific is expected to exhibit fastest growth during the forecast period.


This product will be delivered within 1-3 business days.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AbbVie Inc.
  • Aurobindo Pharma
  • Cipla Inc.
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc.

Chapter 1. Methodology and Scope
1.1. Market segmentation & scope
1.2. Information procurement
1.2.1. Purchased database
1.2.2. internal database
1.2.3. Secondary sources & third-party perspectives
1.2.4. Primary research
1.3. Information analysis
1.3.1. Data analysis models
1.4. Market formulation & data visualization
1.5. Data validation & publishing
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Antiviral Drugs Market Variables, Trends & Scope
3.1. Market Lineage outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Impact of COVID-19 on the Antiviral Drugs Market
3.4. Market Dynamics
3.4.1. Market Driver Analysis
3.4.1.1. Increasing prevalence of viral infections such as hepatitis and HIV
3.4.1.2. Presence of pipeline products for HIV treatment
3.4.1.3. Increasing geriatric population
3.4.2. Market Restraint Analysis
3.4.2.1. Presence of generics
3.4.2.2. Rising awareness and preventive treatments
3.5. Antiviral Drugs: Market Analysis Tools
3.5.1. Industry Analysis - Porter’s
3.5.1.1. Supplier Power
3.5.1.2. Buyer Power
3.5.1.3. Substitution Threat
3.5.1.4. Threat from new entrant
3.5.1.5. Competitive rivalry
3.5.2. PESTEL Analysis
3.5.2.1. Political Landscape
3.5.2.2. Environmental Landscape
3.5.2.3. Social Landscape
3.5.2.4. Technology Landscape
3.5.2.5. Legal Landscape
Chapter 4. Antiviral Drugs Market: Segment Analysis, By Drug Class, 2017 - 2028 (USD Million)
4.1. Definitions & Scope
4.2. Drug class market share analysis, 2020 & 2028
4.3. Segment Dashboard
4.4. Global Antiviral Drugs Market, By Drugs Class, 2017 to 2028
4.5. Market Size & Forecasts and Trend Analyses, 2017 to 2028 for the following
4.5.1. DNA Polymerase Inhibitors
4.5.2. Reverse Transcriptase Inhibitors
4.5.3. Protease Inhibitors
4.5.4. Neuraminidase Inhibitors
4.5.5. Others
Chapter 5. Antiviral Drugs Market: Segment Analysis, By Type, 2017 - 2028 (USD Million)
5.1. Definitions & Scope
5.2. Type market share analysis, 2020 & 2028
5.3. Segment Dashboard
5.4. Global Antiviral Drugs Market, By Type, 2017 to 2028
5.5. Market Size & Forecasts and Trend Analyses, 2017 to 2028 for the following
5.5.1. Branded
5.5.2. Generics
Chapter 6. Antiviral Drugs Market: Segment Analysis, By Application, 2017 - 2028 (USD Million)
6.1. Definitions & Scope
6.2. Application market share analysis, 2020 & 2028
6.3. Segment Dashboard
6.4. Global Antiviral Drugs Market, By Application, 2017 to 2028
6.5. Market Size & Forecasts and Trend Analyses, 2017 to 2028 for the following
6.5.1. HIV
6.5.2. Hepatitis
6.5.3. Influenza
6.5.4. Herpes
6.5.5. Others
Chapter 7. Antiviral Drugs Market: Regional Market Analysis, By Region, 2017 - 2028 (USD Million)
7.1. Definitions & Scope
7.2. Regional market share analysis, 2020 & 2028
7.3. Regional Market Dashboard
7.4. Regional Market Share and Leading Players, 2020
7.5. SWOT Analysis, by Factor (Political & Legal, Economic And Technological)
7.5.1. North America
7.5.2. Europe
7.5.3. Asia Pacific
7.5.4. Latin America
7.5.5. Middle East & Africa
7.6. Antiviral Drugs Market Size, & Forecasts and Trend Analysis, 2020 to 2028:
7.7. North America
7.7.1. Antiviral Drugs Market estimates and forecast, by country, 2017 - 2028 (USD Million)
7.7.2. Antiviral Drugs Market estimates and forecast, by drug class, 2017 - 2028 (USD Million)
7.7.3. Antiviral Drugs Market estimates and forecast, by type, 2017 - 2028 (USD Million)
7.7.4. Antiviral Drugs Market estimates and forecast, by application, 2017 - 2028 (USD Million)
7.7.5. U.S.
7.7.5.1. Antiviral Drugs Market estimates and forecast, by drug class, 2017 - 2028 (USD Million)
7.7.5.2. Antiviral Drugs Market estimates and forecast, by type, 2017 - 2028 (USD Million)
7.7.5.3. Antiviral Drugs Market estimates and forecast, by application, 2017 - 2028 (USD Million)
7.7.6. Canada
7.7.6.1. Antiviral Drugs Market estimates and forecast, by drug class, 2017 - 2028 (USD Million)
7.7.6.2. Antiviral Drugs Market estimates and forecast, by type, 2017 - 2028 (USD Million)
7.7.6.3. Antiviral Drugs Market estimates and forecast, by application, 2017 - 2028 (USD Million)
7.8. Europe
7.8.1. Antiviral Drugs Market estimates and forecast, by country, 2017 - 2028 (USD Million)
7.8.2. Antiviral Drugs Market estimates and forecast, by drug class, 2017 - 2028 (USD Million)
7.8.3. Antiviral Drugs Market estimates and forecast, by type, 2017 - 2028 (USD Million)
7.8.4. Antiviral Drugs Market estimates and forecast, by application, 2017 - 2028 (USD Million)
7.8.5. Germany
7.8.5.1. Antiviral Drugs Market estimates and forecast, by drug class, 2017 - 2028 (USD Million)
7.8.5.2. Antiviral Drugs Market estimates and forecast, by type, 2017 - 2028 (USD Million)
7.8.5.3. Antiviral Drugs Market estimates and forecast, by application, 2017 - 2028 (USD Million)
7.8.6. U.K.
7.8.6.1. Antiviral Drugs Market estimates and forecast, by drug class, 2017 - 2028 (USD Million)
7.8.6.2. Antiviral Drugs Market estimates and forecast, by type, 2017 - 2028 (USD Million)
7.8.6.3. Antiviral Drugs Market estimates and forecast, by application, 2017 - 2028 (USD Million)
7.8.7. France
7.8.7.1. Antiviral Drugs Market estimates and forecast, by drug class, 2017 - 2028 (USD Million)
7.8.7.2. Antiviral Drugs Market estimates and forecast, by type, 2017 - 2028 (USD Million)
7.8.7.3. Antiviral Drugs Market estimates and forecast, by application, 2017 - 2028 (USD Million)
7.8.8. Italy
7.8.8.1. Antiviral Drugs Market estimates and forecast, by drug class, 2017 - 2028 (USD Million)
7.8.8.2. Antiviral Drugs Market estimates and forecast, by type, 2017 - 2028 (USD Million)
7.8.8.3. Antiviral Drugs Market estimates and forecast, by application, 2017 - 2028 (USD Million)
7.8.9. Spain
7.8.9.1. Antiviral Drugs Market estimates and forecast, by drug class, 2017 - 2028 (USD Million)
7.8.9.2. Antiviral Drugs Market estimates and forecast, by type, 2017 - 2028 (USD Million)
7.8.9.3. Antiviral Drugs Market estimates and forecast, by application, 2017 - 2028 (USD Million)
7.9. Asia Pacific
7.9.1. Antiviral Drugs Market estimates and forecast, by country, 2017 - 2028 (USD Million)
7.9.2. Antiviral Drugs Market estimates and forecast, by drug class, 2017 - 2028 (USD Million)
7.9.3. Antiviral Drugs Market estimates and forecast, by type, 2017 - 2028 (USD Million)
7.9.4. Antiviral Drugs Market estimates and forecast, by application, 2017 - 2028 (USD Million)
7.9.5. China
7.9.5.1. Antiviral Drugs Market estimates and forecast, by drug class, 2017 - 2028 (USD Million)
7.9.5.2. Antiviral Drugs Market estimates and forecast, by type, 2017 - 2028 (USD Million)
7.9.5.3. Antiviral Drugs Market estimates and forecast, by application, 2017 - 2028 (USD Million)
7.9.6. Japan
7.9.6.1. Antiviral Drugs Market estimates and forecast, by drug class, 2017 - 2028 (USD Million)
7.9.6.2. Antiviral Drugs Market estimates and forecast, by type2017 - 2028 (USD Million)
7.9.6.3. Antiviral Drugs Market estimates and forecast, by application, 2017 - 2028 (USD Million)
7.9.7. India
7.9.7.1. Antiviral Drugs Market estimates and forecast, by drug class, 2017 - 2028 (USD Million)
7.9.7.2. Antiviral Drugs Market estimates and forecast, by type, 2017 - 2028 (USD Million)
7.9.7.3. Antiviral Drugs Market estimates and forecast, by application, 2017 - 2028 (USD Million)
7.9.8. Australia
7.9.8.1. Antiviral Drugs Market estimates and forecast, by drug class, 2017 - 2028 (USD Million)
7.9.8.2. Antiviral Drugs Market estimates and forecast, by type2017 - 2028 (USD Million)
7.9.8.3. Antiviral Drugs Market estimates and forecast, by application, 2017 - 2028 (USD Million)
7.9.9. South Korea
7.9.9.1. Antiviral Drugs Market estimates and forecast, by drug class, 2017 - 2028 (USD Million)
7.9.9.2. Antiviral Drugs Market estimates and forecast, by type, 2017 - 2028 (USD Million)
7.9.9.3. Antiviral Drugs Market estimates and forecast, by application, 2017 - 2028 (USD Million)
7.10. Latin America
7.10.1. Antiviral Drugs Market estimates and forecast, by country, 2017 - 2028 (USD Million)
7.10.2. Antiviral Drugs Market estimates and forecast, by drug class, 2017 - 2028 (USD Million)
7.10.3. Antiviral Drugs Market estimates and forecast, by type, 2017 - 2028 (USD Million)
7.10.4. Antiviral Drugs Market estimates and forecast, by application, 2017 - 2028 (USD Million)
7.10.5. Brazil
7.10.5.1. Antiviral Drugs Market estimates and forecast, by drug class, 2017 - 2028 (USD Million)
7.10.5.2. Antiviral Drugs Market estimates and forecast, by type, 2017 - 2028 (USD Million)
7.10.5.3. Antiviral Drugs Market estimates and forecast, by application, 2017 - 2028 (USD Million)
7.10.6. Mexico
7.10.6.1. Antiviral Drugs Market estimates and forecast, by drug class, 2017 - 2028 (USD Million)
7.10.6.2. Antiviral Drugs Market estimates and forecast, by type, 2017 - 2028 (USD Million)
7.10.6.3. Antiviral Drugs Market estimates and forecast, by application, 2017 - 2028 (USD Million)
7.10.7. Argentina
7.10.7.1. Antiviral Drugs Market estimates and forecast, by drug class, 2017 - 2028 (USD Million)
7.10.7.2. Antiviral Drugs Market estimates and forecast, by type, 2017 - 2028 (USD Million)
7.10.7.3. Antiviral Drugs Market estimates and forecast, by application, 2017 - 2028 (USD Million)
7.10.8. Colombia
7.10.8.1. Antiviral Drugs Market estimates and forecast, by drug class, 2017 - 2028 (USD Million)
7.10.8.2. Antiviral Drugs Market estimates and forecast, by type, 2017 - 2028 (USD Million)
7.10.8.3. Antiviral Drugs Market estimates and forecast, by application, 2017 - 2028 (USD Million)
7.11. Middle East and Africa
7.11.1. Antiviral Drugs Market estimates and forecast, by country, 2017 - 2028 (USD Million)
7.11.2. Antiviral Drugs Market estimates and forecast, by drug class, 2017 - 2028 (USD Million)
7.11.3. Antiviral Drugs Market estimates and forecast, by type, 2017 - 2028 (USD Million)
7.11.4. Antiviral Drugs Market estimates and forecast, by application, 2017 - 2028 (USD Million)
7.11.5. South Africa
7.11.5.1. Antiviral Drugs Market estimates and forecast, by drug class, 2017 - 2028 (USD Million)
7.11.5.2. Antiviral Drugs Market estimates and forecast, by type, 2017 - 2028 (USD Million)
7.11.5.3. Antiviral Drugs Market estimates and forecast, by application, 2017 - 2028 (USD Million)
7.11.6. Saudi Arabia
7.11.6.1. Antiviral Drugs Market estimates and forecast, by drug class, 2017 - 2028 (USD Million)
7.11.6.2. Antiviral Drugs Market estimates and forecast, by type2017 - 2028 (USD Million)
7.11.6.3. Antiviral Drugs Market estimates and forecast, by application, 2017 - 2028 (USD Million)
7.11.7. UAE
7.11.7.1. Antiviral Drugs Market estimates and forecast, by drug class, 2017 - 2028 (USD Million)
7.11.7.2. Antiviral Drugs Market estimates and forecast, by type, 2017 - 2028 (USD Million)
7.11.7.3. Antiviral Drugs Market estimates and forecast, by application, 2017 - 2028 (USD Million)
Chapter 8. Antiviral drugs market - Competitive Analysis
8.1. Recent Developments & Impact Analysis, By Key Market Participants
8.2. Company/Competition Categorization (Key innovators, Market leaders, Emerging players)
8.3. Public Companies
8.3.1. Company market position analysis (Revenue, geographic presence, product portfolio, key serviceable industries, key alliances)
8.3.2. Company Market Share/Ranking, by region
8.3.3. Competitive Dashboard Analysis
8.4. Private Companies
8.4.1. List of key emerging companies’ /technology disruptors/innovators
8.4.2. Regional network map
8.4.3. Company market position analysis
8.5. Key companies profiled
8.5.1. Gilead Sciences, Inc.
8.5.1.1. Company Overview
8.5.1.2. Financial Performance
8.5.1.3. Product Benchmarking
8.5.1.4. Strategic Initiatives
8.5.2. F. Hoffmann-La Roche Ltd.
8.5.2.1. Company Overview
8.5.2.2. Financial Performance
8.5.2.3. Product Benchmarking
8.5.2.4. Strategic Initiatives
8.5.3. GlaxoSmithKline plc.
8.5.3.1. Company Overview
8.5.3.2. Financial Performance
8.5.3.3. Product Benchmarking
8.5.3.4. Strategic Initiatives
8.5.4. AbbVie Inc.
8.5.4.1. Company Overview
8.5.4.2. Financial Performance
8.5.4.3. Product Benchmarking
8.5.4.4. Strategic Initiatives
8.5.5. Merck & Co., Inc.
8.5.5.1. Company Overview
8.5.5.2. Financial Performance
8.5.5.3. Product Benchmarking
8.5.5.4. Strategic Initiatives
8.5.6. Johnson & Johnson Services, Inc.
8.5.6.1. Company Overview
8.5.6.2. Financial Performance
8.5.6.3. Product Benchmarking
8.5.6.4. Strategic Initiatives
8.5.7. Bristol-Myers Squibb Company
8.5.7.1. Company Overview
8.5.7.2. Financial Performance
8.5.7.3. Product Benchmarking
8.5.7.4. Strategic Initiatives
8.5.8. Cipla Inc.
8.5.8.1. Company Overview
8.5.8.2. Financial Performance
8.5.8.3. Product Benchmarking
8.5.8.4. Strategic Initiatives
8.5.9. Aurobindo Pharma
8.5.9.1. Company Overview
8.5.9.2. Financial Performance
8.5.9.3. Product Benchmarking
8.5.9.4. Strategic Initiatives
8.5.10. Dr. Reddy’s Laboratories Ltd.
8.5.10.1. Company Overview
8.5.10.2. Financial Performance
8.5.10.3. Product Benchmarking
8.5.10.4. Strategic Initiatives
List of Tables
Table 1 List of Abbreviations
Table 2 North America Antiviral Drugs Market, By Drug Class, 2017-2028 (USD Million)
Table 3 North America Antiviral Drugs Market, By Type, 2017-2028 (USD Million)
Table 4 North America Antiviral Drugs Market, By Application, 2017-2028 (USD Million)
Table 5 U.S. Antiviral Drugs Market, By Drug Class, 2017-2028 (USD Million)
Table 6 U.S. Antiviral Drugs Market, By Type, 2017-2028 (USD Million)
Table 7 U.S. Antiviral Drugs Market, By Application, 2017-2028 (USD Million)
Table 8 Canada Antiviral Drugs Market, By Drug Class, 2017-2028 (USD Million)
Table 9 Canada Antiviral Drugs Market, By Type, 2017-2028 (USD Million)
Table 10 Canada Antiviral Drugs Market, By Application, 2017-2028 (USD Million)
Table 11 Europe Antiviral Drugs Market, By Drug Class, 2017-2028 (USD Million)
Table 12 Europe Antiviral Drugs Market, By Type, 2017-2028 (USD Million)
Table 13 Europe Antiviral Drugs Market, By Application, 2017-2028 (USD Million)
Table 14 Germany Antiviral Drugs Market, By Drug Class, 2017-2028 (USD Million)
Table 15 Germany Antiviral Drugs Market, By Type, 2017-2028 (USD Million)
Table 16 Germany Antiviral Drugs Market, By Application, 2017-2028 (USD Million)
Table 17 U.K. Antiviral Drugs Market, By Drug Class, 2017-2028 (USD Million)
Table 18 U.K. Antiviral Drugs Market, By Type, 2017-2028 (USD Million)
Table 19 U.K. Antiviral Drugs Market, By Application, 2017-2028 (USD Million)
Table 20 Italy Antiviral Drugs Market, By Drug Class, 2017-2028 (USD Million)
Table 21 Italy Antiviral Drugs Market, By Type, 2017-2028 (USD Million)
Table 22 Italy Antiviral Drugs Market, By Application, 2017-2028 (USD Million)
Table 23 France Antiviral Drugs Market, By Drug Class, 2017-2028 (USD Million)
Table 24 France Antiviral Drugs Market, By Type, 2017-2028 (USD Million)
Table 25 France Antiviral Drugs Market, By Application, 2017-2028 (USD Million)
Table 26 Spain Antiviral Drugs Market, By Drug Class, 2017-2028 (USD Million)
Table 27 Spain Antiviral Drugs Market, By Type, 2017-2028 (USD Million)
Table 28 Spain Antiviral Drugs Market, By Application, 2017-2028 (USD Million)
Table 29 Asia Pacific Antiviral Drugs Market, By Drug Class, 2017-2028 (USD Million)
Table 30 Asia Pacific Antiviral Drugs Market, By Type, 2017-2028 (USD Million)
Table 31 Asia Pacific Antiviral Drugs Market, By Application, 2017-2028 (USD Million)
Table 32 Japan Antiviral Drugs Market, By Drug Class, 2017-2028 (USD Million)
Table 33 Japan Antiviral Drugs Market, By Type, 2017-2028 (USD Million)
Table 34 Japan Antiviral Drugs Market, By Application, 2017-2028 (USD Million)
Table 35 China Antiviral Drugs Market, By Drug Class, 2017-2028 (USD Million)
Table 36 China Antiviral Drugs Market, By Type, 2017-2028 (USD Million)
Table 37 China Antiviral Drugs Market, By Application, 2017-2028 (USD Million)
Table 38 India Antiviral Drugs Market, By Drug Class, 2017-2028 (USD Million)
Table 39 India Antiviral Drugs Market, By Type, 2017-2028 (USD Million)
Table 40 India Antiviral Drugs Market, By Application, 2017-2028 (USD Million)
Table 41 South Korea Antiviral Drugs Market, By Drug Class, 2017-2028 (USD Million)
Table 42 South Korea Antiviral Drugs Market, By Type, 2017-2028 (USD Million)
Table 43 South Korea Antiviral Drugs Market, By Application, 2017-2028 (USD Million)
Table 44 Australia Antiviral Drugs Market, By Drug Class, 2017-2028 (USD Million)
Table 45 Australia Antiviral Drugs Market, By Type, 2017-2028 (USD Million)
Table 46 Australia Antiviral Drugs Market, By Application, 2017-2028 (USD Million)
Table 47 Latin America Antiviral Drugs Market, By Drug Class, 2017-2028 (USD Million)
Table 48 Latin America Antiviral Drugs Market, By Type, 2017-2028 (USD Million)
Table 49 Latin America Antiviral Drugs Market, By Application, 2017-2028 (USD million)
Table 50 Brazil Antiviral Drugs Market, By Drug Class, 2017-2028 (USD Million)
Table 51 Brazil Antiviral Drugs Market, By Type, 2017-2028 (USD Million)
Table 52 Brazil Antiviral Drugs Market, By Application, 2017-2028 (USD Million)
Table 53 Mexico Antiviral Drugs Market, By Drug Class, 2017-2028 (USD Million)
Table 54 Mexico Antiviral Drugs Market, By Type, 2017-2028 (USD Million)
Table 55 Mexico Antiviral Drugs Market, By Application, 2017-2028 (USD Million)
Table 56 Argentina Antiviral Drugs Market, By Drug Class, 2017-2028 (USD Million)
Table 57 Argentina Antiviral Drugs Market, By Type, 2017-2028 (USD Million)
Table 58 Argentina Antiviral Drugs Market, By Application, 2017-2028 (USD Million)
Table 59 Colombia Antiviral Drugs Market, By Drug Class, 2017-2028 (USD Million)
Table 60 Colombia Antiviral Drugs Market, By Type, 2017-2028 (USD Million)
Table 61 Colombia Antiviral Drugs Market, By Application, 2017-2028 (USD Million)
Table 62 MEA Antiviral Drugs Market, By Drug Class, 2017-2028 (USD Million)
Table 63 MEA Antiviral Drugs Market, By Type, 2017-2028 (USD Million)
Table 64 MEA Antiviral Drugs Market, By Application, 2017-2028 (USD Million)
Table 65 South Africa Antiviral Drugs Market, By Drug Class, 2017-2028 (USD Million)
Table 66 South Africa Antiviral Drugs Market, By Type, 2017-2028 (USD Million)
Table 67 South Africa Antiviral Drugs Market, By Application, 2017-2028 (USD Million)
Table 68 UAE Antiviral Drugs Market, By Drug Class, 2017-2028 (USD Million)
Table 69 UAE Antiviral Drugs Market, By Type, 2017-2028 (USD Million)
Table 70 UAE Antiviral Drugs Market, By Application, 2017-2028 (USD Million)
Table 71 Saudi Arabia Antiviral Drugs Market, By Drug Class, 2017-2028 (USD Million)
Table 72 Saudi Arabia Antiviral Drugs Market, By Type, 2017-2028 (USD Million)
Table 73 Saudi Arabia Antiviral Drugs Market, By Application, 2017-2028 (USD Million)
List of Figures
Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Market summary
Fig. 4 Market segmentation & scope
Fig. 5 Market size and growth prospects
Fig. 6 Global antiviral drugs market-Key market driver analysis
Fig. 7 Global antiviral drugs market-Key market restraint analysis
Fig. 8 Penetration & growth prospect mapping
Fig. 9 Global antiviral drugs market-Porter’s analysis
Fig. 10 Global antiviral drugs market-PESTEL analysis
Fig. 11 Global antiviral drugs market drug class outlook key takeaways
Fig. 12 Global antiviral drugs market: Drug class movement analysis
Fig. 13 DNA polymerase inhibitors market estimates, 2017-2028 (USD Million)
Fig. 14 Reverse transcriptase inhibitors market estimates, 2017-2028 (USD Million)
Fig. 15 Protease inhibitors market estimates, 2017-2028 (USD Million)
Fig. 16 Neuraminidase inhibitors market estimates, 2017-2028 (USD Million)
Fig. 17 Others market estimates, 2017-2028 (USD Million)
Fig. 18 Global antiviral drugs market Type outlook key takeaways
Fig. 19 Global antiviral drugs market: Type movement analysis
Fig. 20 Branded market estimates, 2017-2028 (USD Million)
Fig. 21 Generics market estimates, 2017-2028 (USD Million)
Fig. 22 Global antiviral drugs market Application outlook key takeaways
Fig. 23 Global antiviral drugs market: Application movement analysis
Fig. 24 HIV market estimates, 2017-2028 (USD Million)
Fig. 25 Hepatitis market estimates, 2017-2028 (USD Million)
Fig. 26 Influenza market estimates, 2017-2028 (USD Million)
Fig. 27 Herpes market estimates, 2017-2028 (USD Million)
Fig. 28 Others market estimates, 2017-2028 (USD Million)
Fig. 29 Regional marketplace: Key takeaways
Fig. 30 Global antiviral drugs market: Regional movement analysis
Fig. 31 North America antiviral drugs market, 2017-2028 (USD Million)
Fig. 32 U.S. antiviral drugs market, 2017-2028 (USD Million)
Fig. 33 Canada antiviral drugs market, 2017-2028 (USD Million)
Fig. 34 Europe antiviral drugs market, 2017-2028 (USD Million)
Fig. 35 U.K. antiviral drugs market, 2017-2028 (USD Million)
Fig. 36 Germany antiviral drugs market, 2017-2028 (USD Million)
Fig. 37 France antiviral drugs market, 2017-2028 (USD Million)
Fig. 38 Spain antiviral drugs market, 2017-2028 (USD Million)
Fig. 39 Italy antiviral drugs market, 2017-2028 (USD Million)
Fig. 40 Asia Pacific antiviral drugs market, 2017-2028 (USD Million)
Fig. 41 Japan antiviral drugs market, 2017-2028 (USD Million)
Fig. 42 China antiviral drugs market, 2017-2028 (USD Million)
Fig. 43 India antiviral drugs market, 2017-2028 (USD Million)
Fig. 44 South Korea antiviral drugs market, 2017-2028 (USD Million)
Fig. 45 Australia antiviral drugs market, 2017-2028 (USD Million)
Fig. 46 Latin America antiviral drugs market, 2017-2028 (USD Million)
Fig. 47 Brazil antiviral drugs market, 2017-2028 (USD Million)
Fig. 48 Mexico antiviral drugs market, 2017-2028 (USD Million)
Fig. 49 Argentina antiviral drugs market, 2017-2028 (USD Million)
Fig. 50 Colombia antiviral drugs market, 2017-2028 (USD Million)
Fig. 51 MEA antiviral drugs market, 2017-2028 (USD Million)
Fig. 52 South Africa antiviral drugs market, 2017-2028 (USD Million)
Fig. 53 Saudi Arabia antiviral drugs market, 2017-2028 (USD Million)
Fig. 54 UAE market, 2017-2028 (USD Million)
Fig. 55 Strategy framework
Note: Product cover images may vary from those shown

Loading
LOADING...

  • Gilead Sciences, Inc.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc.
  • AbbVie Inc.
  • Merck & Co., Inc.
  • Johnson & Johnson Services, Inc.
  • Bristol-Myers Squibb Company
  • Cipla Inc.
  • Aurobindo Pharma
  • Dr. Reddy’s Laboratories Ltd.
Note: Product cover images may vary from those shown

Loading
LOADING...